Effectiveness and safety of tripterygium glycosides tablet (SIC)) for lupus nephritis: a systematic review and Meta-analysis

OBJECTIVE: To investigate the effectiveness and safety of tripterygium glycosides (TG) tablet ((SIC)) for the treatment of Lupus nephritis (LN). METHODS: Several databases were systematically searched including PubMed, Embase, Cochrane, Wiley, China National Knowledge Infrastructure Database, SinoMed and Wanfang Library till June 20, 2020. Revman5.3 was utilized to analyze the data according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement. RESULTS: In total, 8 randomized controlled trials involving 583 participants were identified. Meta-analyses showed that, compared with glucocorticoids (GC) alone, the combination with TG tablet provided a statistically significant improvement in total remission (TR) (RR =1.27, 95% CI: 1.08-1.50, P = 0.004), complete remission (CR) (RR = 1.61, 95% CI: 1.05-2.47, P = 0.03) and C3 levels (WMD = 0.27, 95% CI: 0.14-0.39, P < 0.000 1), C4 levels (WMD = 0.12, 95% CI: 0.07-0.17, P < 0.000 01). No significant differences were seen in TR, CR, proteinuria, serum creatinine, C3 and C4 (TR: RR = 1.00, 95% CI: 0.87-1.16, P = 0.95; CR: RR = 1.10, 95% CI: 0.78-1.56, P = 0.58; proteinuria levels: WMD =-0.06, 95% CI:-0.13 to 0.01, P = 0.10; serum creatinine levels: WMD =-0.01, 95%CI:-7.36 to 7.35, P = 1.00; C3 levels: WMD = 0.01, 95%CI:-0.06 to 0.07, P = 0.84; C4 levels: WMD =-0.01, 95%CI:-0.03 to 0.01, P = 0.49) between azathioprine (AZA) / leflomit (LEF) + GC and TG tablet + GC. Adverse events (hepatic dysfunction, nausea, vomitting) showed no statistical differences between the TG tablet + GC group and the GC group. There were more new onset of irregular menstruation in the TG tablet + GC group than those in the AZA + GC (RR = 3.57, 95% CI: 1.40-9.11, P = 0.008) /LEF+ GC (RR = 6.69, 95% CI: 2.42-18.46, P = 0.000 2) group, but leucopenia lower than those in AZA + GC group (RR = 0.38, 95% CI: 0.17-0.85, P = 0.02) and alopecia (RR = 0.14, 95% CI: 0.03-0.77, P = 0.02) and rash (RR = 0.09, 95% CI: 0.01-0.69, P = 0.02) lower than those in LEF + GC group. Conclusions: This review indicates that TG tablet maybe effective in LN treatment. Nevertheless, adverse events cannot be ignored. Large sample, multi-center, high -quality clinical studies are needed to verify the exact effects and safety of TG tablet in treatment of LN. (C) 2022 JTCM. All rights reserved.